Investing $500 per Month in This ETF Could Set You Up for Life, According to History
Warren Buffett was right when he said, “There seems to be some perverse human characteristic that likes to make easy things difficult.” Too many investors are constantly hunting for the next great growth stock, only to suffer avoidable setbacks by owning the wrong risky stocks. These people could do at least as well —
Gold falls on firm dollar, spotlight on Fed's rate decision
Gold pure gold bar models captured in Shanghai, China on March 15, 2026.
Cfoto | Future Publishing | Getty Images
Gold retreated on Tuesday, weighed down by a firm dollar, as investors hunkered down for the Federal Reserve’s policy verdict at the end of its two-day meeting this week for insight into the direction of U.S.
» Read more about: Gold falls on firm dollar, spotlight on Fed's rate decision »
Read MoreTwo VIPB-managed mutual funds declare up to 5% cash dividends for FY26
Highlights:
- VIPB SEBL 1st Unit Fund declares 5% cash dividend
- VIPB NLI 1st Unit Fund announces 4% cash dividend
- Both funds generated total returns of around 20% in FY26
- Company attributes performance to disciplined value-investing strategy
Two open-ended mutual funds managed by VIPB Asset Management Company Limited have announced cash dividends for the fiscal year ended 30 June 2026 after posting strong returns.
» Read more about: Two VIPB-managed mutual funds declare up to 5% cash dividends for FY26 »
Read MoreUS Federal Reserve’s direction of travel on interest rates has rarely been this opaque
The outcome of Wednesday’s US Federal Reserve meeting, the second under chairman Kevin Warsh, is one of the most unpredictable in years.
Markets, in the main, are expecting the central bank to hold interest rates steady, but some observers say a moderate rate hike in response to spiking oil prices isn’t off the table.
Read MoreTech Stocks Tumble on Worries Over A.I. Spending and China’s Chips
A global technology stock sell-off intensified on Tuesday, underpinned by worries over hefty bills for the build-out of artificial intelligence systems and concerns over tougher competition from China.
The Nasdaq Composite index, chock-full of big technology companies, came close on Tuesday to falling into correction, Wall Street’s term of a drop of 10 percent or more from its recent peak,
» Read more about: Tech Stocks Tumble on Worries Over A.I. Spending and China’s Chips »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Why This Beverage Giant Can’t Be Toppled
A famous book on business was titled Barbarians at the Gate, documenting the leveraged buyout of RJR Nabisco. If nothing else, it highlights how just the sniff of an opportunity to make money can drive money seekers to make wild decisions.
Some giant businesses have been on the receiving end of similar threats to their solvency as invaders attempt to take their share.
» Read more about: Why This Beverage Giant Can’t Be Toppled »